CN1135904A - Oral liquid of shengxueyin - Google Patents

Oral liquid of shengxueyin Download PDF

Info

Publication number
CN1135904A
CN1135904A CN 95110240 CN95110240A CN1135904A CN 1135904 A CN1135904 A CN 1135904A CN 95110240 CN95110240 CN 95110240 CN 95110240 A CN95110240 A CN 95110240A CN 1135904 A CN1135904 A CN 1135904A
Authority
CN
China
Prior art keywords
radix
oral liquid
shengxueyin
day
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 95110240
Other languages
Chinese (zh)
Other versions
CN1053363C (en
Inventor
唐延军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN95110240A priority Critical patent/CN1053363C/en
Publication of CN1135904A publication Critical patent/CN1135904A/en
Application granted granted Critical
Publication of CN1053363C publication Critical patent/CN1053363C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A Chinese-medicinal oral liquid suitable for radiotherapy and chemicotherapy to promote growth of leucocytes and prevent bone marrow inhibition is prepared from 14 Chinese-medicinal materials such as spatholobus stem, astragalus root, lucid ligustrum fruit, lucid ganoderma, pilose asiabell root, etc. through purifying and sterilizing by alcohol, and decoction in aseptic water.

Description

Oral liquid of shengxueyin
The invention belongs to a kind of leukocyte of promotion growth that has, the Chinese herbal medicine oral liquid of control bone marrow depression function.
At present, 60 cobalt radiotherapies and cyclophosphamide (being called for short CTX) chemotherapy are mainly adopted in the treatment of various malignant tumor.These two kinds of therapeutic modalities all destroy the intravital leukocyte of patient to some extent, produce negative interaction.For making smooth the hitting the target the course of treatment of treatment, most hospitals all adopt the leucogen, batyl alcohol, and adenine phosphate, polyactin, medicines such as Colla Corii Asini slurry prevent and treat bone marrow depression, but effect are all not obvious to promote leukocyte growth in patient's body.
The purpose of this invention is to provide a kind of promotion leukocyte growth, prevent and treat the double Chinese herbal medicine oral liquid of protecting the type of building of myelosuppressive treatment.
Oral liquid of shengxueyin is a kind of Chinese herbal medicine oral liquid, and the weight ratio of its drug component is followed successively by:
Caulis Spatholobi 0.15~0.3: the Radix Astragali 0.1~0.2: Fructus Ligustri Lucidi 0.1~0.2:
Ganoderma 0.05~0.1: Radix Codonopsis 0.05~0.1: Radix Angelicae Sinensis 0.05~0.1:
Herba Epimedii 0.01~0.15: Radix Glycyrrhizae 0.1~0.15: Radix Asparagi 0.1~0.15:
Rhizoma Dioscoreae 0.1~0.15: Cortex Cinnamomi 0.05~0.1: Radix Et Caulis Acanthopanacis Senticosi 0.1~0.15:
Radix Rehmanniae Preparata 0.15~0.2: Fructus Rubi 0.1~0.2
Preparation method of the present invention is: above 14 flavor medical herbs are soaked half an hour, decoct then three times, be blended into ethanol after the gained mixed liquor concentrates and purify, make reflow of alcohol after the purification, cooled and filtered, bottling sterilization at last.
The oral liquid of shengxueyin that adopts the said method infusion is a kind of Chinese herbal and crude drugs preparations for the treatment of the health of holding concurrently, because it is soft, be applicable to that the each age group patient takes, particularly to weak and sickly gerontal patient with can not to finish patient's effect of treatment plan to the ability to bear difference of radiotherapy and chemotherapy particularly remarkable.
1993, through the paired observation test that railway hospital in Dalian carries out 1321 routine tumor patients, result of the test proved: the patient who takes oral liquid of shengxueyin finishes and radiocurablely reaches 92.9%.In addition, do experiment effect also clearly with mice:
One, CTX is handled the therapeutic effect of mice
Mice is divided into three groups by the body weight stratified random, makes between group the average weight difference basically less than 1.0 grams.Each is organized first day and irritates stomach CTX once by 100mg/kg.d. dosage, and every day is irritated the stomach oral liquid of shengxueyin in beginning in second day, 20 milliliters/kilogram of high dose group, and 10 milliliters/kilogram of low dose group, matched group is irritated the stomach normal saline once a day, successive administration four days.Got tail vein, and looked into total white blood cells in the 6th day.Obtain the leukocyte rate of rise by following formula:
Figure A9511024000041
The results are shown in Table 1. leukogenic effect is arranged.High dose group is compared with matched group, and leukocyte raises 27,5%, P value<0.02, significant difference.
Table 1. couple CTX handles the therapeutic effect of mice
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm)
20 10 20 18.83 11112±3194 <0.02
10 10 19.7 18.4 8977 ± 2442 contrasts 10 19.7 18.8 8717 ± 2835
Two, give the therapeutic effect of CTX after the protection of administration in advance again
Mice is divided into three groups (method is the same) by the body weight stratified random.Each is organized and irritates the stomach oral liquid of shengxueyin every day, 20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group.Matched group is irritated the stomach normal saline.Once a day, successive administration is eight days.The 5th day each group increases irritates stomach CTX once, and dosage is that 10mg/kg.d. got tail vein on the 9th day, looks into total white blood cells, calculates leukocyte rate of rise (the same).
The results are shown in Table 2. leukogenic effect is arranged.High dose group is compared with matched group, and leukocyte raises 43.8%, P value<0.005, difference highly significant.
Give therapeutic effect group mice body weight (gram) leukocyte count of CTX after the table 2. administration in advance protection again
Experiment back before N P value (milliliter/kilogram) experiment is (individual/mm) 20 11 19.6 19.5 14327 ± 3761<0.005 10 11 19.8 18.7 12181 ± 3335 contrasts 12 19.5 19.0 9966 ± 2217
Three, CTX is handled the protection effect of mice
Mice is divided into three groups (method is the same) by the body weight stratified random.Each is organized first day and irritates stomach CTX once by 60mg/kg.d. dosage, begins to irritate the stomach oral liquid of shengxueyin in second day.20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group, matched group is irritated the stomach normal saline.Once a day, successive administration is three days.Reach administration before the administration and get tail vein after three days, look into total white blood cells.Obtain the protection effect by following formula:
Though the results are shown in Table leukocyte counts of 3. each group, compare all and descend after the administration with before the administration, grand down more obvious of matched group, have only administration preceding 65.1%, P value<0.05.High dose group then is 86.6% before the administration, and P value>0.05 presents the protection effect after administration is described.
Table 3. couple CTX handles the protection effect of mice
Group leukocyte count (individual/mm3) (gram)
Administration is after three days before the administration of N protection effect P value (milliliter/kilogram)
8018±2112 6945±2926
20 11 1.33 >0.05
(100) (86.6)
9307±2829 6390±1393
10 11 1.05
1100 168.61
10352±4228 6736±2303
Contrast 11>0.05
(100) (65.1)
Four, 60 cobalts are handled the therapeutic effect of mice
Mice is divided into three groups (method is the same) by the body weight stratified random.Each organizes first day by S=400cm2, and skin is apart from 75cm, the rectangular once irradiating 60 cobalt rays of accumulated dose 100Cry.Began to irritate the stomach oral liquid of shengxueyin in second day, 20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group.Matched group is irritated the stomach normal saline.Day once, successive administration six days.Got tail vein, and looked into total white blood cells in the 8th day.Calculate leukocyte rate of rise (method is the same).
It is comparatively obvious to the results are shown in Table 4. leukogenic effects.High dose group is compared with matched group, and leukocyte raises 53.8%, P value<0.005, difference highly significant.
Table 4. pair 60 cobalts are handled the therapeutic effect of mice
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm3)
20 10 19.7 20.1 10505±2601 <0.005
10 10 19.7 21.55 8505±3690
Contrast 10 19.85 21.7 6830 ± 2193
Five, shine 60 cobaltic therapeutic effect again after the protection of administration in advance
Mice is divided into two groups (method is the same) by the body weight stratified random.Experimental group is irritated 10 milliliters/kilogram of stomach oral liquid of shengxueyin every day, and matched group is irritated the stomach normal saline.Once a day, successive administration is eight days.Each group press S=400cm in the 4th day, and skin is apart from 75cm, accumulated dose 100Cry, rectangular once irradiating cobalt ray.Get tail vein on the 9th day, and looked into total white blood cells, calculate leukocyte rate of rise (method is the same).
It is comparatively obvious to the results are shown in Table 5. leukogenic effects.Experimental group is compared with matched group, and leukocyte raises 48%, P value<0.005, difference highly significant.
Shine 60 cobaltic therapeutic effect again after the table 5. administration in advance protection
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm)
10 11 19.8 22.6 10468±2921 <0.005
Contrast 12 20 23.8 7070 ± 1797
Oral liquid of shengxueyin of the present invention is achieved by the following technical solution:
1. the present invention's prescription as follows: (unit gram)
Caulis Spatholobi 30; The Radix Astragali 20; Fructus Ligustri Lucidi 20; Ganoderma 10; Radix Codonopsis 10;
Radix Angelicae Sinensis 10; The sheep leaves of pulse plants 15; Radix Glycyrrhizae 15; Radix Asparagi 15; Rhizoma Dioscoreae 15;
Cortex Cinnamomi 10; Radix Et Caulis Acanthopanacis Senticosi 15; Radix Rehmanniae Preparata 20; Fructus Rubi 20.
Above-mentioned 14 flavor medicines are put into jar add after 1000 gram sterilized water soak half an hour, divides three decoction, decocting time is identical, puts into sterilized water 500 during second and third time decoction more respectively and restrains.Three decoction gained medicinal liquid 500 grams that are concentrated into admixed together, the ethanol that adds 1000 grams 97% carries out purification processes, and vaporized alcohol is refluxed, and cooled and stored was used filter paper filtering after 48 hours.Bottle at last and use γShe Xianmiejun.
2. also prescription in the following manner of the present invention: (unit gram)
Caulis Spatholobi 15; The Radix Astragali 10; Fructus Ligustri Lucidi 10; Ganoderma 5; Radix Codonopsis 5; Radix Angelicae Sinensis 5; Herba Epimedii 10; Radix Glycyrrhizae 10; Radix Asparagi 10; Rhizoma Dioscoreae 10; Cortex Cinnamomi 5; Radix Et Caulis Acanthopanacis Senticosi 10; Radix Rehmanniae Preparata 15; Fructus Rubi 10.Concrete preparation method is with 1.

Claims (1)

1. an oral liquid of shengxueyin is to promote the leukocyte growth, prevents and treats myelosuppressive Chinese herbal medicine oral liquid, it is characterized in that the weight ratio that contains drug component is followed successively by:
Caulis Spatholobi 0.15~0.3: the Radix Astragali 0.1~0.2: Fructus Ligustri Lucidi 0.1~0.2:
Ganoderma 0.05~0.1: Radix Codonopsis 0.05~0.1: Radix Angelicae Sinensis 0.05~0.1:
Herba Epimedii 0.01~0.15: Radix Glycyrrhizae 0.1~0.15: Radix Asparagi 0.1~0.15:
Rhizoma Dioscoreae 0.1~0.15: Cortex Cinnamomi 0.05~0.1: Radix Et Caulis Acanthopanacis Senticosi 0.1~0.15:
Radix Rehmanniae Preparata 0.15~0.2: Fructus Rubi 0.1~0.2
CN95110240A 1995-05-16 1995-05-16 Oral liquid of shengxueyin Expired - Fee Related CN1053363C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN95110240A CN1053363C (en) 1995-05-16 1995-05-16 Oral liquid of shengxueyin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95110240A CN1053363C (en) 1995-05-16 1995-05-16 Oral liquid of shengxueyin

Publications (2)

Publication Number Publication Date
CN1135904A true CN1135904A (en) 1996-11-20
CN1053363C CN1053363C (en) 2000-06-14

Family

ID=5077644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95110240A Expired - Fee Related CN1053363C (en) 1995-05-16 1995-05-16 Oral liquid of shengxueyin

Country Status (1)

Country Link
CN (1) CN1053363C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943661B (en) * 2005-10-08 2010-11-10 周小明 A Chinese traditional medicinal composition and its preparation method
US20110236511A1 (en) * 2008-09-25 2011-09-29 Life Biotech Medical Research Ltd Herbal formulations
CN104306698A (en) * 2014-09-30 2015-01-28 哈尔滨乐泰药业有限公司 Traditional Chinese medicine composition for enhancing human body immunity, as well as preparation method and application thereof
CN104491267A (en) * 2015-01-08 2015-04-08 李宏 Traditional Chinese medicine composition for alleviating bone marrow inhibition effect caused by chemotherapy and preparation method thereof
CN105726776A (en) * 2016-03-03 2016-07-06 郑州大学 Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943661B (en) * 2005-10-08 2010-11-10 周小明 A Chinese traditional medicinal composition and its preparation method
US20110236511A1 (en) * 2008-09-25 2011-09-29 Life Biotech Medical Research Ltd Herbal formulations
US8574636B2 (en) * 2008-09-25 2013-11-05 Lifebiotic Medical Research Ltd Herbal formulations
US9370543B2 (en) 2008-09-25 2016-06-21 Lifebiotic Medical Research Ltd Herbal formulations
US10172904B2 (en) 2008-09-25 2019-01-08 Lifebiotic Medical Research Ltd Herbal formulations
CN104306698A (en) * 2014-09-30 2015-01-28 哈尔滨乐泰药业有限公司 Traditional Chinese medicine composition for enhancing human body immunity, as well as preparation method and application thereof
CN104306698B (en) * 2014-09-30 2017-05-17 哈尔滨乐泰药业有限公司 Traditional Chinese medicine composition for enhancing human body immunity, as well as preparation method and application thereof
CN104491267A (en) * 2015-01-08 2015-04-08 李宏 Traditional Chinese medicine composition for alleviating bone marrow inhibition effect caused by chemotherapy and preparation method thereof
CN105726776A (en) * 2016-03-03 2016-07-06 郑州大学 Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy

Also Published As

Publication number Publication date
CN1053363C (en) 2000-06-14

Similar Documents

Publication Publication Date Title
CN1943689A (en) A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method
CN1046205C (en) External use Chinese traditional medicine for curing diarrhea
CN1053363C (en) Oral liquid of shengxueyin
CN1124156C (en) Chinese-medicinal pills for treating rheumatism and preparing process thereof
CN1054773C (en) Chinese patent drug "Bizhengning" for treatment of arthralgia-syndrome
CN1045169C (en) Adhesive plaster capable of detoxicating and resolving a mass
CN110934924A (en) Traditional Chinese medicine bone marrow hematogenesis composition and application thereof
CN1060657C (en) Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method
CN1116545A (en) Brain-refreshing analgesic powder medicine
CN1083725C (en) Cordyceps medicinal composition and its preparing method
CN1136939A (en) Chinese drugs for curing hepatitis B
CN1179978A (en) Drug composition for curing osteoporosis
CN1190229C (en) Medicine for curing hepatitis B
CN1257739C (en) Senshitong mixture for treating nephrolithiasis
CN1059800C (en) Injection containing ginseng and astragalus root components
CN1101559A (en) Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method
CN1216623C (en) Blood pressure reducing and stabiliaing Chinese medicine and its prepn
CN1091382C (en) Compound Lingxian headache-treating capsule and its preparation
CN1042495C (en) Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn.
CN1100312A (en) Bai cao sheng shou oral liquid
CN1463192A (en) Herb compsns. for treating dopy and agrypnia
CN1513539A (en) Preparation technology of supplementing kind capsule
CN1075725C (en) Medicaments for treating thrombocytopenic purpura and anaemia
CN1059115C (en) Drug composition for curing osteoporosis
CN1111055C (en) Ichthyosis treating cream and its preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee